Physician profile
Lance T Lee
NPI 1578820569
$4,035.78
in general payments reported to CMS, 2019-2025
33 companies · $844 in 2025
The $844 reported for 2025 was more than what 90% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $478 · 2020: $267 · 2021: $27.50 · 2022: $570 · 2023: $1,251 · 2024: $600 · 2025: $844.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,694.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $764.65 | 2020-2025 | |
| Novo Nordisk INC | $368.95 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $315.67 | 2019-2025 | Farxiga, Airsupra |
| Merck Sharp & Dohme LLC | $289.65 | 2019-2025 | Pifeltro |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $256.74 | 2022-2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $233.26 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Viiv Healthcare Company | $199.77 | 2022-2025 | Dovato, Apretude, Rukobia |
| Imperative Care, INC | $197.15 | 2023 | Zoom 88-T Large Distal Platform |
| Pfizer INC. | $189.09 | 2019-2025 | |
| Glaxosmithkline, LLC. | $170.38 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $169.73 | 2019-2023 | |
| Idorsia Pharmaceuticals US INC | $108.57 | 2023 | Quviviq |
| Ucb, INC. | $83.67 | 2024 | Rystiggo |
| Sunovion Pharmaceuticals INC. | $81.97 | 2019-2021 | |
| Daiichi Sankyo INC. | $76.72 | 2024-2025 | Injectafer |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $61.50 | 2022-2025 | |
| Indivior INC. | $49.12 | 2022-2025 | Sublocade |
| Viatris Specialty LLC | $47.58 | 2025 | Yupelri |
| Alkermes, INC. | $45.99 | 2023 | Aristada, Lybalvi |
| Biohaven Pharmaceutical Holding Company LTD. | $42.03 | 2022 | |
| Exact Sciences Corporation | $41.07 | 2023 | Cologuard Collection Kit |
| Theratechnologies INC. | $32.82 | 2019 | |
| Phathom Pharmaceuticals, INC. | $30.57 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $29.30 | 2025 | Rexulti |
| Collegium Pharmaceutical, INC. | $23.79 | 2022 | |
| Covis Pharma Gmbh | $20.77 | 2022 | |
| Janssen Biotech, INC. | $17.28 | 2019 | |
| Amgen INC. | $15.86 | 2020 | |
| Mylan Specialty L.P. | $15.69 | 2023 | Yupelri |
| Allergan, INC. | $15.00 | 2020 | |
| Amarin Pharma, INC. | $14.55 | 2019 | |
| Emd Serono, INC. | $14.46 | 2020 | |
| Livanova USA, INC. | $12.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lance Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.